Ivermectin mass drug administration (MDA) in humans to reduce malaria vectors is yet another use for this remarkable medicine whose discoverers shared the 2015 Nobel Prize in Medicine with the discoverer of artemisinin.
Exports of artemisinin derivatives for China have been transforming from API-dominated to FPP-dominated.
The fight against mosquito-borne diseases is a challenge of huge public health importance.
With proper malaria diagnosis, SP may still be used as a rational anti-malarial drug either as a single prescription or in combination with artemisinin.
Whole-genome sequencing technologies are being increasingly applied to Plasmodium falciparum clinical isolates to identify genetic determinants of malaria pathogenesis.
Paul Russell’s Man’s Mastery of Malaria (1), written in 1955, opens with these wistful words: “While keeping in mind the realities, one can nevertheless be confident that malaria is well on its way toward oblivion
Following a decade of gains in malaria control, two divergent prospects are emerging:
Artemisinin, also known as qinghaosu, is a sesquiterpene lactone endoperoxide extracted from the plant Artemisia annua L, an herb employed in traditional Chinese medicine.
These results highlight the normal distribution of early parasitological responses following ACT, and the influence that heterogeneity in study design, host and parasite factors have in confounding a surveillance system based on Day 3 parasite positivity.
In this framework, an anti-malarial pharmacovigilance plan was developed and implemented in all public health services. This study investigated the occurrence of Adverse Drug Events (ADEs) after ACT.